First two patients enrolled in a clinical trial to treat Group 2 PH
A press release announced that the first two patients have enrolled in a trial of a treatment for Group 2 pulmonary hypertension (PH associated with left heart disease). The treatment procedure is minimally invasive and aims to reduce overactive nerve signals that might contribute to changes in the blood vessels in the lungs and to worsening heart and lung disease. Earlier studies confirmed that the procedure was safe and showed potential benefits.
This procedure is also being explored to treat pulmonary arterial hypertension (Group 1 PH). There are no specific treatments for Group 2 PH yet, so it will be interesting to follow this study.
Comments